122 related articles for article (PubMed ID: 2795755)
1. Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ.
Studer UE; Casanova G; Kraft R; Zingg EJ
J Urol; 1989 Oct; 142(4):975-7. PubMed ID: 2795755
[TBL] [Abstract][Full Text] [Related]
2. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
Thalmann GN; Markwalder R; Walter B; Studer UE
J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
[TBL] [Abstract][Full Text] [Related]
4. [Percutaneous Bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ].
Yamashita S; Yogi Y; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Kubota S
Hinyokika Kiyo; 1992 Oct; 38(10):1095-9. PubMed ID: 1481770
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract.
Yokogi H; Wada Y; Mizutani M; Igawa M; Ishibe T
Br J Urol; 1996 May; 77(5):676-9. PubMed ID: 8689109
[TBL] [Abstract][Full Text] [Related]
6. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy.
Kojima Y; Tozawa K; Kawai N; Sasaki S; Hayashi Y; Kohri K
Int J Urol; 2006 Apr; 13(4):340-4. PubMed ID: 16734847
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
[TBL] [Abstract][Full Text] [Related]
9. [Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract].
Okubo K; Ishitoya S; Maeda H; Suzuki Y; Arai Y
Nihon Hinyokika Gakkai Zasshi; 1997 Mar; 88(3):386-90. PubMed ID: 9125861
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ.
Shapiro EY; Lipsky MJ; Cha DY; McKiernan JM; Benson MC; Gupta M
J Endourol; 2012 Dec; 26(12):1645-50. PubMed ID: 22834939
[TBL] [Abstract][Full Text] [Related]
11. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
12. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous BCG perfusion of the upper urinary tract for carcinoma in situ.
Studer UE; Casanova G; Kraft R; Zingg EJ
Prog Clin Biol Res; 1989; 310():207-12. PubMed ID: 2771994
[No Abstract] [Full Text] [Related]
14. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
15. Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ.
Sharpe JR; Duffy G; Chin JL
J Urol; 1993 Mar; 149(3):457-9; discussion 459-60. PubMed ID: 8437246
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
Lamm DL
J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
[TBL] [Abstract][Full Text] [Related]
18. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
[TBL] [Abstract][Full Text] [Related]
19. [Intrarenal Bacillus Calmette-Guerin perfusion therapy was effective for carcinoma in situ of the upper urinary tract after ileal conduit replacement : a case report].
Hayashi T; Yamanaka Y; Kinjo T; Katayama K; Kamoto A; Mori N; Yoshioka T
Hinyokika Kiyo; 2014 Apr; 60(4):175-8. PubMed ID: 24882229
[TBL] [Abstract][Full Text] [Related]
20. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
